Roche Holding AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas Schinecker
- Full Time Employees
- 103,249
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Grenzacherstrasse 124 Basel BS Switzerland 4070
- IPO Date
- Aug 3, 2012
- Website
- roche.com
- Similar Companies
- Business
- Roche Holding AG is a Swiss multinational healthcare company that discovers, develops, and markets innovative medicines and diagnostic tests. The company operates through two primary segments: Pharmaceuticals, which focuses on oncology, immunology, infectious diseases, ophthalmology, and neurology; and Diagnostics, which provides clinical chemistry, coagulation, and molecular diagnostics solutions. Its core products and services include pharmaceutical brands such as Tecentriq (atezolizumab) for cancer immunotherapy, Hemlibra (emicizumab) for hemophilia A, Ocrevus (ocrelizumab) for multiple sclerosis, Evrysdi (risdiplam) for spinal muscular atrophy, and Actemra/RoActemra (tocilizumab) for rheumatoid arthritis and cytokine release syndrome; diagnostic offerings encompass the cobas platform for in vitro diagnostics, including cobas pro integrated solutions, Accu-Chek for diabetes management, and Ventana for pathology testing. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland, with global operations spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East, serving healthcare professionals, patients, and research institutions. In recent developments, the company expanded its diagnostics portfolio through the 2024 launch of the cobas 5800 analyser system for high-volume clinical chemistry testing and strengthened its oncology pipeline via a strategic collaboration with Regeneron Pharmaceuticals announced in late 2024 to co-develop faricimab for additional indications; additionally, Roche completed the acquisition of Poseida Therapeutics in mid-2025 for $1.5 billion to bolster its cell therapy capabilities in hematology and solid tumors.
Company News
Roche Partners With China's Hansoh in Deal That Could Top $15 Billion
Roche to unveil lung, breast cancer data at ESMO 2026
Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
Roche Gets FDA Approval for Another Label Expansion of Tecentriq
BAYRY vs. RHHBY: Which Stock Should Value Investors Buy Now?
Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas Transcript
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
Roche outlines plans to move towards autonomous AI labs
NTHM's Index Rebalance Puts Thematic Rotation to Work
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Roche: Latest Obesity Data Suggests Pharma Is In Line To Become Global GLP-1 Player
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease